XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information
 6 Months Ended
Jun. 30, 2021
Segment Information  
Segment Information

Note 14 — Segment Information

​

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products.  Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

​

Abbott’s reportable segments are as follows:

​

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

​

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

​

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites.  For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

​

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products.  For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology and Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

​

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements.  Segment disclosures are on a performance basis consistent with internal management reporting.  Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost.  Remaining costs, if any, are not allocated to segments.  In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

​

Note 14 — Segment Information (Continued)

​

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Sales to External Customers

​

Operating Earnings

​

​

Three Months

​

Six Months

​

Three Months

​

Six Months

​

​

Ended June 30

​

Ended June 30

​

Ended June 30

​

Ended June 30

(in millions)

    

2021

    

2020

    

2021

    

2020

    

2021

    

2020

    

2021

    

2020

Established Pharmaceutical Products

​

$

1,180

​

$

1,013

​

$

2,250

​

$

2,057

​

$

220

​

$

206

​

$

389

​

$

387

Nutritional Products

​

 

2,108

​

 

1,883

​

 

4,144

​

 

3,787

​

 

490

​

 

474

​

 

957

​

 

933

Diagnostic Products

​

 

3,247

​

 

1,994

​

 

7,261

​

 

3,820

​

 

1,076

​

 

522

​

 

2,777

​

 

927

Medical Devices

​

 

3,666

​

 

2,423

​

 

6,986

​

 

5,360

​

 

1,208

​

 

391

​

 

2,215

​

 

1,194

Total Reportable Segments

​

 

10,201

​

 

7,313

​

 

20,641

​

 

15,024

​

 

2,994

​

 

1,593

​

 

6,338

​

​

3,441

Other

​

 

22

​

 

15

​

 

38

​

 

30

​

​

​

​

​

​

​

​

​

​

​

​

Net sales

​

$

10,223

​

$

7,328

​

$

20,679

​

$

15,054

​

​

​

​

​

​

​

​

​

​

​

​

Corporate functions and benefit plan costs

​

​

​

​

​

​

​

​

​

​

​

​

 

​

(132)

​

​

(106)

​

​

(246)

​

​

(238)

Net interest expense

​

​

​

​

​

​

​

​

​

​

​

​

 

​

(123)

​

​

(125)

​

​

(247)

​

​

(246)

Share-based compensation (a)

​

​

​

​

​

​

​

​

​

​

​

​

 

​

(132)

​

​

(115)

​

​

(420)

​

​

(348)

Amortization of intangible assets

​

​

​

​

​

​

​

​

​

​

​

​

 

​

(504)

​

​

(553)

​

​

(1,013)

​

​

(1,114)

Other, net (b)

​

​

​

​

​

​

​

​

​

​

​

​

 

​

(755)

​

​

(168)

​

​

(1,021)

​

​

(336)

Earnings from continuing operations before taxes

​

​

​

​

​

​

​

​

​

​

​

​

​

$

1,348

​

$

526

​

$

3,391

​

$

1,159

(a)Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)Other, net for the three and six months ended June 30, 2021 and 2020 includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. 2021 restructuring charges include $499 million related to Abbott’s restructuring plan for its COVID-19 test manufacturing network.  Other, net for the three and six months ended June 30, 2021 also includes costs related to certain litigation.  Other, net for the three and six months ended June 30, 2020 also includes impairments of equity investments.

​